At least 50 million malaria patient a year could benefit from the first new drug developed by
the 2-year-old Drugs for Neglected Disease initiative (DNDi). A patent-free, fixeddose …

The global fight against malaria has been continually challenged by poor access to
affordable, effective medicine. Growing resistance to chloroquine, the traditional treatment …

ACOMPLEX MIX OF FACTORS—lack of funds and political will, drug shortages, and
complicated drug regimens—have stood in the way of more effective malaria treatment in …

In 2004, the Institute of Medicine concluded that a global high-level subsidy was the best
way to make effective antimalarial drugs—currently, artemisinin-combination therapies …

In 2004, the Institute of Medicine (IOM) proposed a simple solution to a pressing global
problem (Arrow et al. 2004). The price of artemisinin-based combination therapies (ACTs) …

The increasing death toll from drug-resistant falciparum malaria is cause for international
concern. In 2002, the US Agency for International Development commissioned the Institute …

The Affordable Medicines Facility-malaria is an innovative financing mechanism, managed
by the Global Fund to Fight AIDS, Tuberculosis and Malaria. This initiative aims to increase …

The success or failure of any public health program is largely determined by the public's
effective use of the services offered. This principle is especially relevant in treating malaria …

An independent evaluation of the Affordable Medicine Facility for malaria (AMFm) pilot
phase has hailed it as a success, but important limitations and unanswered questions …

For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured
billions of debilitating infections. Today, however, these drugs no longer work against the …